Evidence map›Paper›PMID 26002321›Full record

ReviewBiochimica et biophysica acta2015

Antimicrobial peptide resistance in Neisseria meningitidis.

Yih-Ling Tzeng, David S Stephens

Abstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Management and prevention of Neisseria meningitidis and Neisseria gonorrhoeae infections in the context of evolving antimicrobial resistance trends.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Review
  3. Review
  4. Bacteriophage steering ofJournal of bacteriology · 2023
    Article
  5. Article
  6. Article
  7. The Host-Pathogen Interactions and Epicellular Lifestyle ofFrontiers in cellular and infection microbiology · 2022
    Review
  8. Emergence of a novel urogenital-tropic Neisseria meningitidis.Current opinion in infectious diseases · 2021
    Review
  9. Article
  10. A Rare Mutation in SPLUNC1 Affects Bacterial Adherence and Invasion in Meningococcal Disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Yih-Ling TzengDepartment of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
David S StephensDepartment of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA; Laboratories of Microbial Pathogenesis, Medical Research Service, Veterans Affairs Medical Center, Decatur, GA 30033, USA. Electronic address: dstep01@emory.edu.
Atlanta VA Medical Center · USEmory University · US

Funding

MENINGOCOCCAL LIPOOLIGOSACCHARIDE &MUCOSAL PATHOGENESISR01AI033517 · NIAID · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 1993 to 2007
$1.7M
Control of virulence in Neisseria meningitidisR01AI061031 · NIAID · EMORY UNIVERSITY · PI TZENG, YIH-LING · 2005 to 2009
$1.5M
REGULATION OF CAPSULE BIOSYNTHESIS IN N MENINGITIDISR01AI040247 · NIAID · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 1997 to 2006
$1.2M
Control of virulence in Neisseria meningitidisR56AI061031 · NIAID · EMORY UNIVERSITY · PI TZENG, YIH-LING · 2012 to 2012
$351k
NIAID NIH HHS 5R01 AI040247NIAID NIH HHS R01 AI033517NIAID NIH HHS R01 AI040247NIAID NIH HHS R01 AI061031NIAID NIH HHS R56 AI061031
6 · The paper itself

Abstract

Antimicrobial peptides (AMPs) play an important role as a host defense against microbial pathogens and are key components of the human innate immune response. Neisseria meningitidis frequently colonizes the human nasopharynx as a commensal but also is a worldwide cause of epidemic meningitis and rapidly fatal sepsis. In the human respiratory tract, the only known reservoir of N. meningitidis, meningococci are exposed to human endogenous AMPs. Thus, it is not surprising that meningococci have evolved effective mechanisms to confer intrinsic and high levels of resistance to the action of AMPs. This article reviews the current knowledge about AMP resistance mechanisms employed by N. meningitidis. Two major resistance mechanisms employed by meningococci are the constitutive modification of the lipid A head groups of lipooligosaccharides by phosphoethanolamine and the active efflux pump mediated excretion of AMPs. Other factors influencing AMP resistance, such as the major porin PorB, the pilin biogenesis apparatus, and capsular polysaccharides, have also been identified. Even with an inherently high intrinsic resistance, several AMP resistance determinants can be further induced upon exposure to AMPs. Many well-characterized AMP resistance mechanisms in other Gram-negative bacteria are not found in meningococci. Thus, N. meningitidis utilizes a limited but highly effective set of molecular mechanisms to mediate antimicrobial peptide resistance. This article is part of a Special Issue entitled: Bacterial Resistance to Antimicrobial Peptides.

Indexed as

Drug Resistance, BacterialAnimalsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesBacterial ProteinsHost-Pathogen InteractionsHumansImmune EvasionImmunity, InnateLipid AMembrane Transport ProteinsMeningitis, MeningococcalMicrobial ViabilityNeisseria meningitidisSignal TransductionAnti-Bacterial AgentsAntimicrobial Cationic PeptidesBacterial ProteinsLipid AMembrane Transport ProteinsAntimicrobial resistanceEfflux pumpNeisseria meningitidisPhosphoethanolamine modification of lipid A

Identifiers

PMID26002321
PMCPMC4605851
OpenAlexW2173229060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.